Elutia (NASDAQ: ELUT) has announced a new GPO agreement with Advantus Health Partners, marking its seventh GPO agreement since launching EluPro™. The agreement will expand access to EluPro™, the world's first FDA-cleared antibiotic-eluting biologic envelope for cardiac implantable electronic devices and neurostimulators.
EluPro™ combines antibiotics with a natural extracellular matrix that regenerates into patient tissue, addressing post-surgical challenges including infection, migration, and skin erosion. Dr. Kimberly Mulligan, GM and VP of Elutia's Cardiovascular Division, noted that the pilot launch has exceeded expectations, with physicians recognizing the product's unique value in preventing infections.
The partnership with Advantus Health Partners, a healthcare solutions company specializing in supply chain management and cost-savings efficiencies, will help make EluPro™ more widely available to physicians nationwide through their sustainable contracting solutions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.